Kristina Lindsten
Redwood Pharma (Sweden)(SE)
Publications by Year
Research Areas
Ubiquitin and proteasome pathways, Autophagy in Disease and Therapy, Cancer, Hypoxia, and Metabolism, Endoplasmic Reticulum Stress and Disease, Genetics and Neurodevelopmental Disorders
Most-Cited Works
- → Short-lived green fluorescent proteins for quantifying ubiquitin/proteasome-dependent proteolysis in living cells(2000)612 cited
- → Inhibition of proteasome deubiquitinating activity as a new cancer therapy(2011)494 cited
- → Viral immune modulators perturb the human molecular network by common and unique strategies(2012)270 cited
- → A transgenic mouse model of the ubiquitin/proteasome system(2003)238 cited
- → Mutant ubiquitin found in neurodegenerative disorders is a ubiquitin fusion degradation substrate that blocks proteasomal degradation(2002)224 cited
- → The ER‐resident ubiquitin‐specific protease 19 participates in the UPR and rescues ERAD substrates(2009)152 cited
- → Lack of Proteasome Active Site Allostery as Revealed by Subunit-Specific Inhibitors(2001)120 cited
- → Stressing the ubiquitin-proteasome system(2009)84 cited
- → Inhibition of proteasomal degradation by the Gly-Ala repeat of Epstein–Barr virus is influenced by the length of the repeat and the strength of the degradation signal(2000)83 cited
- → Ubiquitin-specific Protease 19 (USP19) Regulates Hypoxia-inducible Factor 1α (HIF-1α) during Hypoxia(2011)81 cited